A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

NCT00976989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: FEC
DRUG: Docetaxel
DRUG: TCH

Sponsor

Hoffmann-La Roche